Resveratrol in Type2 Diabetes and Obesity
|ClinicalTrials.gov Identifier: NCT01158417|
Recruitment Status : Unknown
Verified December 2012 by Paresh Dandona, MD, Kaleida Health.
Recruitment status was: Active, not recruiting
First Posted : July 8, 2010
Last Update Posted : December 18, 2012
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Obesity Insulin Resistance||Drug: Placebo Drug: Resveratrol 40 mg oral three times a day Drug: Resveratrol 500 mg oral once daily.||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||102 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects|
|Study Start Date :||December 2008|
|Estimated Primary Completion Date :||April 2014|
|Estimated Study Completion Date :||August 2014|
Placebo Comparator: Placebo
Experimental: Resveratrol 40 mg oral three times a day
Drug: Resveratrol 40 mg oral three times a day
Experimental: resveratrol 500 mg oral once daily.
Drug: Resveratrol 500 mg oral once daily.
Resveratrol 500 mg oral once daily.
- NF-Kb [ Time Frame: 12 weeks ]To investigate the effect of resveratrol on ROS generation and the pro-inflammatory transcription factor NF-kB
- GLP-1 [ Time Frame: 12 weeks ]To see whether Resveratrol leads to a greater stimulation of the incretin system and secretion/release of GIP and GLP-1 when compared to that following placebo
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01158417
|United States, New York|
|115 Flint Road|
|Buffalo, New York, United States, 14221|
|Principal Investigator:||Paresh Dandona, MD||Kaleida Health|